IP Library › Granted Patent US 12,351,650
Granted Patent B2
US 12,351,650 · App. 18/755,457 · Granted Jul 8, 2025

Antibodies binding to fibroblast activation protein alpha and death receptor 4

Inventors: Bart E.C.G. De Goeij (Maarssen, NL); Ilse Jongerius (De Bilt, NL); Grietje Andringa (Utrecht, NL); Madelon Paauwe (The Hague, NL); Theodorus Sjouke Plantinga (Duiven, NL); David Satijn (Nieuwegein, NL); Jamila Laoukili (Zeist, NL); Onno Wouter Kranenburg (Zeist, NL); Marije Overdijk (Utrecht, NL)
Assignee: GENMAB A/S
C07K16/468A61P35/04G01N33/6854A61K2039/505C07K2317/31C07K2317/524C07K2317/526C07K2317/53C07K2317/565G01N2800/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,650
App. No.
18/755,457
Granted
Jul 8, 2025
Kind
B2
Abstract

The present invention relates to a multispecific antibody comprising at least a FAPα binding region comprising a first heavy chain variable region and a first light chain variable region; and a DR4 binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Claims (73)

1. A bispecific antibody comprising at least

(i) a fibroblast activation protein alpha (FAPα) binding region comprising a heavy chain variable (VH) region and a light chain variable (VL) region, and

(ii) a death receptor 4 (DR4) binding region comprising a VH region and a VL region,

wherein the VH region of the FAPα binding region comprises the three complementarity determining regions, CDR1, CDR2, and CDR3, present within the amino acid sequence set forth in SEQ ID NO: 13, and the VL region of the FAPα binding region comprises the three complementarity determining regions, CDR1, CDR2, and CDR3, present within the amino acid sequence set forth in SEQ ID NO: 14.

2. The bispecific antibody of claim 1 , wherein the VH region of the FAPα binding region comprises an amino acid sequence which is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO: 13 and the VL region of the FAPα binding region comprises an amino acid sequence which is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO: 14.

3. The bispecific antibody of claim 1 , wherein the DR4 binding region comprises a heavy chain variable region (VH) comprising the three complementarity determining regions, CDR1, CDR2, and CDR3, present within the amino acid sequence set forth in SEQ ID NO: 15, and a light chain variable region (VL) comprising the three complementarity determining regions, CDR1, CDR2, and CDR3, present within the amino acid sequence set forth in SEQ ID NO: 16.

4. The bispecific antibody of claim 1 , wherein the VH region of the DR4 binding region comprises an amino acid sequence which is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO: 15, and the VL region of the DR4 binding region comprises an amino acid sequence which is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO: 16.

5. The bispecific antibody of claim 1 , wherein the antibody comprises:

(i) a FAPα binding region comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 1, 2 and 3, respectively, and the VL region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 4, the sequence VAS, and SEQ ID NO: 6, respectively; and

(ii) a DR4 binding region comprising a VH region and a VL region, wherein the VH comprises the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 7, 8 and 9, respectively, and the VL region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 10, the sequence EVT, and SEQ ID NO: 12, respectively.

6. The bispecific antibody of claim 1 , wherein the antibody comprises:

(i) a FAPα binding region comprising a VH region comprising the amino acid sequence of SEQ ID NO: 13 and a VL region comprising the amino acid sequence of SEQ ID NO: 14; and

(ii) a DR4 binding region comprising a VH region comprising the amino acid sequence of SEQ ID NO: 15 and a VL region comprising the amino acid sequence of SEQ ID NO: 16.

7. The bispecific antibody of claim 1 , wherein the antibody comprises a first heavy chain and a second heavy chain, the first heavy chain comprises the VH region of the FAPα binding region and the second heavy chain comprises the VH region of the DR4 binding region,

(i) wherein each of the first heavy chain and the second heavy chain comprises at least a hinge region, a CH2 region and a CH3 region, and

(ii) wherein in the first heavy chain at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain is substituted, and in the second heavy chain at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain is substituted,

wherein the amino acid positions are as defined by Eu numbering.

8. The bispecific antibody of claim 1 , wherein the antibody comprises a first heavy chain and a second heavy chain, wherein in at least one of the first heavy chain and the second heavy chain one or more amino acids in the positions corresponding to L234, L235, G236, D265, N297, and P331 in a human IgG1 heavy chain are not L, L, G, D, N, and P, respectively, wherein the amino acid positions are as defined by Eu numbering.

9. The bispecific antibody of claim 1 , wherein the antibody comprises a first heavy chain and a second heavy chain, wherein in at least one of the first heavy chain and the second heavy chain:

(a) the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain are F and E, respectively, in the first and/or second heavy chains;

(b) the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain are F, E, and A, respectively, in the first and/or second heavy chains;

(c) the positions corresponding to positions L234, L235, and G236 in a human IgG1 heavy chain are F, E, and R, respectively, in the first and/or second heavy chains; or

(d) one of the first and second heavy chains comprises substitutions of the amino acids corresponding to the amino acids at positions L234, L235 and G236 to F, E and R, respectively, and the other heavy chain comprises substitutions of the amino acids corresponding to the amino acids at positions L234, L235 and D265 to F, E and A, respectively,

wherein the amino acid positions are as defined by Eu numbering.

10. The bispecific antibody of claim 1 , wherein the antibody comprises a first heavy chain and a second heavy chain, and wherein:

(a) the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain of both the first heavy chain and the second heavy chain are F and E, respectively, and wherein

(i) the position corresponding to F405 in a human IgG1 heavy chain according to Eu numbering of the first heavy chain is L, and the position corresponding to K409 in a human IgG1 heavy chain according to Eu numbering of the second heavy chain is R, or

(ii) the position corresponding to K409 in a human IgG1 heavy chain according to Eu numbering of the first heavy chain is R, and the position corresponding to F405 in a human IgG1 heavy chain according to Eu numbering of the second heavy chain is L;

(b) the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain of both the first heavy chain and the second heavy chain are F, E, and A, respectively, and wherein

(i) the position corresponding to F405 in a human IgG1 heavy chain according to Eu numbering of the first heavy chain is L, and the position corresponding to K409 in a human IgG1 heavy chain according to Eu numbering of the second heavy chain is R, or

(ii) the position corresponding to K409 in a human IgG1 heavy chain according to Eu numbering of the first heavy chain is R, and the position corresponding to F405 in a human IgG1 heavy chain according to Eu numbering of the second heavy chain is L; or

(c) the positions corresponding to positions L234, L235, and G236 in a human IgG1 heavy chain of both the first heavy chain and the second heavy chain are F, E, and R, respectively, and wherein

(i) the position corresponding to F405 in a human IgG1 heavy chain according to Eu numbering of the first heavy chain is L, and the position corresponding to K409 in a human IgG1 heavy chain according to Eu numbering of the second heavy chain is R, or

(ii) the position corresponding to K409 in a human IgG1 heavy chain according to Eu numbering of the first heavy chain is R, and the position corresponding to F405 in a human IgG1 heavy chain according to Eu numbering of the second heavy chain is L;

wherein the amino acid positions are as defined by Eu numbering.

11. The bispecific antibody of claim 1 , wherein the antibody comprises a first heavy chain and a second heavy chain, and wherein both the first heavy chain and the second heavy chain comprise substitutions of the amino acids corresponding to the amino acids at positions L234, L235 and G236 to F, E and R, respectively and wherein

(i) the position corresponding to F405 in a human IgG1 heavy chain according to Eu numbering of the first heavy chain is L, and the position corresponding to K409 in a human IgG1 heavy chain according to Eu numbering of the second heavy chain is R, or

(ii) the position corresponding to K409 in a human IgG1 heavy chain according to Eu numbering of the first heavy chain is R, and the position corresponding to F405 in a human IgG1 heavy chain according to Eu numbering of the second heavy chain is L,

wherein the amino acid positions are as defined by Eu numbering.

12. The bispecific antibody of claim 1 , wherein the antibody comprises a kappa (κ) and/or a lambda (λ) light chain.

13. The bispecific antibody according to claim 1 , wherein the antibody comprises two heavy chains and two light chains, wherein one heavy chain comprises a constant region as defined in SEQ ID NO: 26 and the other heavy chain comprises a constant region as defined in SEQ ID NO: 70, and wherein one light chain is a kappa light chain comprising a constant region as defined in SEQ ID NO: 27 and the other light chain is a lambda light chain comprising a constant region as defined in SEQ ID NO: 28.

14. The bispecific antibody of claim 1 , wherein the antibody comprises a first heavy chain and a first light chain connected via disulfide bridges forming a first binding region that binds to FAPα, and a second heavy chain and a second light chain connected via disulfide bridges forming a second binding region that binds to DR4, wherein:

i) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 17 and the first light chain comprises amino acid sequence of SEQ ID NO: 18; and

ii) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 19 and the second light chain comprises the amino acid sequence of SEQ ID NO: 20.

15. A nucleic acid construct, or a combination of nucleic acid constructs, comprising a nucleotide sequence encoding the bispecific antibody of claim 1 .

16. An expression vector, or a combination of expression vectors, comprising the nucleic acid construct, or combination of nucleic acid constructs, of claim 15 .

17. A recombinant host cell comprising the nucleic acid construct, or combination of nucleic acid constructs, of claim 15 .

18. A pharmaceutical composition comprising the bispecific antibody of claim 1 , and a pharmaceutically-acceptable carrier.

19. A method of treating cancer comprising administering to a subject in need thereof an effective amount of the bispecific antibody of claim 1 .

20. The method of claim 19 , wherein the cancer is a solid cancer.

21. The method of claim 19 , wherein the cancer is colorectal cancer, breast cancer, pancreatic cancer, esophagogastric cancer, head and neck squamous cell carcinoma, cervical cancer, or lung cancer.

22. A method for producing a bispecific antibody which binds to fibroblast activation protein alpha (FAPα) and death receptor 4 (DR4), the method comprising:

(a) culturing the recombinant host cell of claim 17 under conditions wherein the antibody is produced; and

(b) isolating the produced antibody from the culture.

23. A method for producing a bispecific antibody which binds to fibroblast activation protein alpha (FAPα) and death receptor 4 (DR4), the method comprising:

(a) providing a first antibody comprising the FAPα binding region and a second antibody comprising the DR4 binding region as defined in claim 1 , wherein the first and second antibodies comprise an Fc region, and wherein the sequences of the first and second CH3 regions of the first and second antibodies are different and are such that the heterodimeric interaction between the first and second CH3 regions is stronger than each of the homodimeric interactions of the first and second CH3 regions;

(b) incubating the first antibody together with the second antibody under reducing conditions sufficient to allow the cysteines in the hinge regions to undergo disulfide-bond isomerization; and

(c) obtaining the antibody comprising the first immunoglobulin heavy chain and the first immunoglobulin light chain of the first antibody and the second immunoglobulin heavy chain and the second immunoglobulin light chain of the second antibody.

24. A kit comprising the bispecific antibody of claim 1 , and instructions for use.

25. The method of claim 20 , wherein the solid cancer is a malignant solid tumor.

26. A bispecific antibody comprising at least

(i) a fibroblast activation protein alpha (FAPα) binding region comprising a heavy chain variable (VH) region and a light chain variable (VL) region, and

(ii) a death receptor 4 (DR4) binding region comprising a VH region and a VL region, wherein the DR4 binding region comprises a heavy chain variable region (VH) comprising the three complementarity determining regions, CDR1, CDR2, and CDR3, present within the amino acid sequence set forth in SEQ ID NO: 15, and a light chain variable region (VL) comprising the three complementarity determining regions, CDR1, CDR2, and CDR3, present within the amino acid sequence set forth in SEQ ID NO: 16.

27. The method of claim 21 , wherein the cancer is colorectal cancer.

28. The method of claim 21 , wherein the cancer is breast cancer.

29. The method of claim 21 , wherein the cancer is pancreatic cancer.

30. The method of claim 21 , wherein the cancer is esophagogastric cancer.

31. The method of claim 21 , wherein the cancer is head and neck squamous cell carcinoma.

32. The method of claim 21 , wherein the cancer is cervical cancer.

33. The method of claim 21 , wherein the cancer is lung cancer.

34. The bispecific antibody of claim 1 , wherein the antibody comprises:

(i) a FAPα heavy chain comprising the amino acid sequence as set forth in SEQ ID NO: 17 and a FAPα light chain comprising the amino acid sequence as set forth in SEQ ID NO: 18, and

(ii) a DR4 heavy chain comprising the amino acid sequence as set forth in SEQ ID NO: 19 and a DR4 light chain comprising the amino acid sequence as set forth in SEQ ID NO: 20.

Assignments (5)
SECURITY INTEREST Recorded Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 073933/0597 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 073949/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2024
From: DE GOEIJ, BART EGBERTUS CORNELIS GIJSBERTUS; JONGERIUS, ILSE; ANDRINGA, GRIETJE; PAAUWE, MADELON; PLANTINGA, THEODORUS SJOUKE; SATIJN, DAVID; OVERDIJK, MARIJE
To: GENMAB A/S
Reel/Frame 068572/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2024
From: LAOUKILI, JAMILA; KRANENBURG, ONNO W.
To: UMC UTRECHT HOLDING B.V.
Reel/Frame 068572/0572 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2024
From: UMC UTRECHT HOLDING B.V.
To: GENMAB A/S
Reel/Frame 068572/0606 →
Priority Claims (1)
EP 23182845 · Jun 30, 2023 · regional
Continuity (1)
Related Publication 20250002610A1 · Jan 2, 2025
References Cited (163)
US 4699880A · Goldstein · 1987 [cited by applicant]
US 5589466A · Felgner et al. · 1996 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5973972A · Kwon et al. · 1999 [cited by applicant]
US 6077835A · Hanson et al. · 2000 [cited by applicant]
US 7262028B2 · Van Berkel et al. · 2007 [cited by applicant]
US 7361341B2 · Salcedo et al. · 2008 [cited by applicant]
US 7612181B2 · Wu et al. · 2009 [cited by applicant]
US 7951918B2 · Glaser et al. · 2011 [cited by applicant]
US 9150663B2 · Labrijn et al. · 2015 [cited by applicant]
US 9212230B2 · Schuurman et al. · 2015 [cited by applicant]
US 9926379B2 · Bruenker et al. · 2018 [cited by applicant]
US 10195156B2 · Benenato et al. · 2019 [cited by applicant]
US 10344050B2 · Gramer et al. · 2019 [cited by applicant]
US 10590206B2 · Labrijn et al. · 2020 [cited by applicant]
US 10597464B2 · Labrijn et al. · 2020 [cited by applicant]
US 10906991B2 · Schuurman et al. · 2021 [cited by applicant]
US 11017533B2 · Gaire · 2021 [cited by examiner]
US 11214622B2 · Bruenker et al. · 2022 [cited by applicant]
US 11485796B2 · Labrijn et al. · 2022 [cited by applicant]
US 11866514B2 · Labrijn et al. · 2024 [cited by applicant]
US 20090136503A1 · Yu et al. · 2009 [cited by applicant]
US 20090304718A1 · Adolf et al. · 2009 [cited by applicant]
US 20100105874A1 · Schuurman et al. · 2010 [cited by applicant]
US 20100155133A1 · Makwinski et al. · 2010 [cited by applicant]
US 20120184718A1 · Bruenker et al. · 2012 [cited by applicant]
US 20130039913A1 · Labrijn et al. · 2013 [cited by applicant]
US 20140303356A1 · Gramer et al. · 2014 [cited by applicant]
US 20150274844A1 · Blankenship et al. · 2015 [cited by applicant]
US 20150337049A1 · Labrijn et al. · 2015 [cited by applicant]
US 20160046727A1 · Labrijn et al. · 2016 [cited by applicant]
US 20160159930A1 · Schuurman et al. · 2016 [cited by applicant]
US 20170233497A1 · Labrijn et al. · 2017 [cited by applicant]
US 20180170866A1 · Payne et al. · 2018 [cited by applicant]
US 20190022247A1 · Ansell et al. · 2019 [cited by applicant]
US 20200048304A1 · Gramer et al. · 2020 [cited by applicant]
US 20200190200A1 · Alfonso Martin et al. · 2020 [cited by applicant]
US 20200262932A1 · Labrijn et al. · 2020 [cited by applicant]
US 20200332022A1 · Labrijn et al. · 2020 [cited by applicant]
US 20210269509A1 · Hibbert · 2021 [cited by examiner]
US 20230227495A1 · Gramer et al. · 2023 [cited by applicant]
US 20230322947A1 · Labrijn et al. · 2023 [cited by applicant]
US 20240150484A1 · De Kreuk et al. · 2024 [cited by applicant]
US 20240209117A1 · Labrijn et al. · 2024 [cited by applicant]
CN 102250246A · 2011 [cited by applicant]
EP 1870459A1 · 2007 [cited by applicant]
EP 2391343A2 · 2011 [cited by applicant]
EP 2972360A1 · 2016 [cited by applicant]
ES 2720433T3 · 2019 [cited by examiner]
WO 9850431A2 · 1998 [cited by applicant]
WO 200046147A2 · 2000 [cited by applicant]
WO 0070087A1 · 2000 [cited by applicant]
WO 2003074569A2 · 2003 [cited by applicant]
WO 2005004809A2 · 2005 [cited by applicant]
WO 2005061547A2 · 2005 [cited by applicant]
WO 2007059782A1 · 2007 [cited by applicant]
WO 2007110205A2 · 2007 [cited by applicant]
WO 2008003116A2 · 2008 [cited by applicant]
WO 2008119353A1 · 2008 [cited by applicant]
WO 2008157379A2 · 2008 [cited by applicant]
WO 2009040562A1 · 2009 [cited by applicant]
WO 2009058383A2 · 2009 [cited by applicant]
WO 2009089004A1 · 2009 [cited by applicant]
WO 2010015792A1 · 2010 [cited by applicant]
WO 2010026923A1 · 2010 [cited by applicant]
WO 2010059315A1 · 2010 [cited by applicant]
WO 2010080538A1 · 2010 [cited by applicant]
WO 2010111625A1 · 2010 [cited by applicant]
WO 2010129304A2 · 2010 [cited by applicant]
WO 2010134666A1 · 2010 [cited by applicant]
WO 2011028952A1 · 2011 [cited by applicant]
WO 2011040972A1 · 2011 [cited by applicant]
WO 2011069104A2 · 2011 [cited by applicant]
WO 2011117329A1 · 2011 [cited by applicant]
WO 2011131746A2 · 2011 [cited by applicant]
WO 2011143545A1 · 2011 [cited by applicant]
WO 2011147986A1 · 2011 [cited by applicant]
WO 2012023053A2 · 2012 [cited by applicant]
WO 2012025525A1 · 2012 [cited by applicant]
WO 2012025530A1 · 2012 [cited by applicant]
WO 2012058768A1 · 2012 [cited by applicant]
WO 2013060867A2 · 2013 [cited by applicant]
WO 2013157953A1 · 2013 [cited by applicant]
WO 2014081202A1 · 2014 [cited by applicant]
WO 2014152774A1 · 2014 [cited by applicant]
WO 2018006052A1 · 2018 [cited by applicant]
WO 2019178438A1 · 2019 [cited by applicant]
WO 2022189667A1 · 2022 [cited by applicant]
Brunker et al. (Mol Cancer Ther (2016) 15 (5): 946-957). [cited by examiner]
Koornstra et al (European Journal of Cancer 41 (2005) 1195-1202). [cited by examiner]
Sykes, K, et al., “Linear expression elements: a rapid, in vivo, method to screen for gene functions,” Nature Biotechology, vol. 17: 355-359 (1999). [cited by applicant]
Van Heeke, G, et al., “Expression of human asparagine synthetase in [cited by applicant]
Ward, E. S. et al., “Binging activities of a repertoire of single immunoglobulin variable domains se-creted from [cited by applicant]
Wigler, M. et al., “Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor,” Cell, vol. 14(3)725-731 (1978). [cited by applicant]
Wranik, B. et al., “LUZ-Y, a Novel Platform for the Mammalian Cell Production of Full-length IgG-bispecific Antibodies,” Journ of Biological Chemistry, vol. 287(52): 43331-43339 (2012). [cited by applicant]
Wu, C., et al., “Generation and Characterization of a Dual Variable Domain Immunoglobin (DVD-Ig (TM)) Molecule,” Springer, Chap. 19: 239-250 (2010). [cited by applicant]
Xin, L. et al., “Fibroblast Activation Protein-a as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review,” Frontiers Editorial Office, vol. 11:648187 (2021). [cited by applicant]
Zhu, X. et al., “COMBODY: one-domain antibody multimer with improved avidity,” Immunology and Cell Biology, vol. 88(6): 667-675 (2010). [cited by applicant]
U.S. Appl. No. 12/593,759, filed Jan. 6, 2010, Janine Schuurman, U.S. Pat. No. 9,212,230. [cited by applicant]
U.S. Appl. No. 14/934,956, filed Nov. 6, 2015, Janine Schuurman, U.S. 10,906,991. [cited by applicant]
U.S. Appl. No. 16/777,053, filed Jan. 30, 2020, Aran Frank Labrijn, U.S. Pat. 11,866,514. [cited by applicant]
U.S. Appl. No. 15/414,122, filed Jan. 24, 2017, Aran Frank Labrijn, U.S. Pat. No. 10,597,464. [cited by applicant]
U.S. Appl. No. 14/830,336, filed Aug. 19, 2015, Aran Frank Labrijn, US 20160046727. [cited by applicant]
U.S. Appl. No. 13/642,253, filed Oct. 24, 2012, Aran Frank Labrijn, U.S. Pat. No. 9,150,663. [cited by applicant]
U.S. Appl. No. 18/507,869, filed Nov. 13, 2023, Aran Frank Labrijn, US 20240209117. [cited by applicant]
U.S. Appl. No. 17/939,736, filed Sep. 7, 2022, Michael Gramer, US 20230227495. [cited by applicant]
U.S. Appl. No. 16/426,647, filed May 30, 2019, Michael Gramer, U.S. Pat. No. 11,492,371. [cited by applicant]
U.S. Appl. No. 14/353,962, filed Apr. 24, 2014, Michael Gramer, U.S. Pat. No. 10,344,050. [cited by applicant]
U.S. Appl. No. 14/760,157, filed Jul. 9, 2015, Aran Frank Labrijn, U.S. Pat. No. 10,590,206. [cited by applicant]
U.S. Appl. No. 16/783,720, filed Feb. 6, 2020, Aran Frank Labrijn, U.S. Pat. No. 11,485,796. [cited by applicant]
U.S. Appl. No. 17/950,350, filed Sep. 22, 2022, Aran Frank Labrijn, US 20230322947. [cited by applicant]
U.S. Appl. No. 16/717,189, filed Dec. 17, 2019, Pedro Jose Alfonso Martin, US 20200190200. [cited by applicant]
U.S. Appl. No. 18/281,372, filed Sep. 11, 2023, Bart-Jan De Kreuk, US 20240150484. [cited by applicant]
Abdiche, Y. et al., “Exploring blocking assays using Octet, ProteOn, and Biacore biosensors,” Anal Biochem., vol. 386(2):172-180 (2009). [cited by applicant]
Ausebel, F. et al., “Current Protocols in Molecular Biology,” Wiley InterScience , 1 page (1987). [cited by applicant]
Barbas, et al., “Molecular Profile of an Antibody Response to HIV-1 as Probed by Combinatorial Li-braries,” Academic Press, vol. 230(3): 812-823 (1993). [cited by applicant]
Benvenisty, N. et al., “Direct introduction of genes into rats and expression of the genes,” PNAS, vol. 83: 9551-9555 (1986). [cited by applicant]
Betts, A. et al., “Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 tran… [cited by applicant]
Bird, R. et al., “Single-Chain Antigen-Binding Proteins,” Science, vol. 242:423-426 (1988). [cited by applicant]
Bitter, G.A., et al., “Expression and secretion vectors for yeast,” Methods in Enxymology, vol. 153: 516-544 (1987). [cited by applicant]
Blankenship JW, et al., “Abstract #5465: CD79BxDR SCORPIONTM molecule: a single chain, bispecific immunotherapeutic with potent in vitro activity against B cell lymphoma,” 4 pages (2009). [cited by applicant]
Bostrom, J. et al., “Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site,” Science, vol. 323:1610-1614 (2009). [cited by applicant]
Brochet X, et al., “IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis,” Nucleic Acids Research, vol. 36: W503-W508 (2008). [cited by applicant]
Chiu, M. et al., “Antibody Structure and Function: The Basis for Engineering Therapeutics,” Antibodies , vol. 8 (55): 80 pages (2019). [cited by applicant]
Corsaro, CM, et al., “Enhancing the efficiency of DNA-mediated gene transfer in mammalian cells,” Somatic Cell Genetic, vol. 7(5),:603-611 (1981). [cited by applicant]
Denney, W.S. et al., “Simple, Automatic Noncompartmental Analysis: The PKNCA R,” J Pharmacoki-net Pharmacodyn, T-51: S65 (2015). [cited by applicant]
Deo, Y. et al., “Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood,” J Immunol vol. 160(4): 16… [cited by applicant]
Di Cristofano, F. et al., “Therapeutic targeting of TRAIL death receptors,” Biochemical Society Transactions, vol. 51(1): 57-70 (2023). [cited by applicant]
Dick, L. et al., “C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes,” Biotechnology and Bioengineering, vol. 100(6):1132-1143 (2008). [cited by applicant]
Dimasi, N. et al., “The Design and Characterization of Oligospecific Antibodies for Simultaneous Tar-geting of Multiple Disease Mediators,” J. Mol. Biol., vol. 393(3): 672-692 (2009). [cited by applicant]
Doppalapudi, V.R., et al., “Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies,” Bioorganic & Medicinal Chemistry Letters, vol. 17: 501-506 vol. (2007). [cited by applicant]
Dubuisson, A. et al., “Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy,” Antibodies, vol. 6(16) 31 pages (2017). [cited by applicant]
Engelberts, P. et al., “DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing,” EBioMedicine, vol. 52 (102625): 5 pages (20… [cited by applicant]
Gramer, M.J., et al., “Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalabil-ity from bench to large-scale manufacturing by application of standard approaches,” MABS, vol. 5(6):962-973 (2013). [cited by applicant]
Hmila, A. et al., “A bispecfic nanobody to provide full protection againstlethal scorpion envenom-ing,” The FASEB Journal, vol. 24: 3479-3489 (2010). [cited by applicant]
Holt, L. J. et al., “Domain antibodies: proteins for therapy,” Trends in Biotechnology, vol. 21(11): 484-490 (2003). [cited by applicant]
International Search Report, PCT/EP2024/068031, dated Nov. 6, 2024, 7 pages. [cited by applicant]
Kabat, E. et al., “Sequences of proteins of Immunological interest,” US Department of Health and Human Services, 1242 pages (1991). [cited by applicant]
Kontermann, R. et al., “Bispecific Antibodies,” Drug Discovery Today, vol. 20(7): 838-847: (2015). [cited by applicant]
Kontermann, R., “Dual targeting strategies with bispecific antibodies,” MABS, 4(2):182-197 (2012). [cited by applicant]
Labrijn, A. et al., “Bispecific antibodies: a mechanistic review of the pipeline,” Nature Reviews, vol. 17: 585-608 (2019). [cited by applicant]
Labrijn, A.F., et al., “Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange,” vol. 110(13): 5145-5150 (2013). [cited by applicant]
Lafleur, D. et al., “Monoclonal antibody therapeutics with up to five specificities: functional en-hancement through fusion of target-specific peptides,” MABS, vol. 5(2): 208-218 (2013). [cited by applicant]
Lawrence, L. et al., “Orientation of antigen binding sites in dimeric and trimeric single chain Fv anti-body fragments,” FEBS, vol. 425(3):479-484 (1998). [cited by applicant]
Le Gall, F. et al., “Effect of linker sequences between the antibody variable domains on the for-mation, stability and biological activity of a bispecific tandem diabody,” Protein Engineering, Design & Selection, vol. 1… [cited by applicant]
Lefranc MP. et al., “ IMGT, the international ImMunoGene Tics database,” Nucleic Acids Re-search, vol. 27 (1):209-212 (1999). [cited by applicant]
Lefranc, M. et al., “The IMGT Unique Numbering for Immunoglobulins, T-Cell Receptors, and Ig-like Domains, ”The Immunologist, vol. 7(4):132-136 (1999). [cited by applicant]
Lefranc, M-P. et al., “IMGTR , the international ImMunoGeneTics information system R 25 years on,” Nucleic Acids Research, vol. 43:D413-422 (2015). [cited by applicant]
Lewis, S. et al., “Generation of bispecific igG antibodies by structure-based design of an orthogonal Fab interface,” Nature Biotechnology, vol. 32(2):191-198 (2014). [cited by applicant]
Lindhofer, H. et al., “Preferential species-restricted heavy/light chain pairing in rat/mouse quad-romas. Implications for a single-step purification of bispecific antibodies,” J. Immunol., vol. 155(1):219-225 (1995). [cited by applicant]
Liu, R. et al., “Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment,” Antibodies, vol. 9(4):457-66 (2020). [cited by applicant]
Lorusso, P. et al., “Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study,” Investigational New Drugs, vol. 40(4): 762-772 (2022). [cited by applicant]
Needleman, S. et al., “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol., vol. 48(3): 443-453 (1970). [cited by applicant]
Papadopoulos, K. et al., “Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetra-valent agonistic Nanobody targeting the DR5 receptor,” Cancer Chenother Pharmacol., vol. 75(5): 887-895 (2015). [cited by applicant]
Patel, A. et al., “In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model,” Cell Reports, vol. 25(7):1982-1993(2018). [cited by applicant]
Pearce, L. et al., “Linear gene fusions of antibody fragments with streptavidin can be linked to bio-tin labelled secondary molecules to form bispecific reagents,” Biochem and Molecular Biology Inter., vol. 42(6): 1179-… [cited by applicant]
Revets, H. et al., “Nanobodies as novel agents for cancer therapy,” Expert Opinion on Biological Therapy, vol. 5 (1):111-124 (2005). [cited by applicant]
Rice, P. et al., “EMBOSS: The European Molecular Biology Open Software Suite,” The European Mo-lecular Biology Open Software Suite, vol. 16(6): 276-277 (2000). [cited by applicant]
Schakowski, F. et al., “A novel minimal-size vector (MIDGE) improves transgene expression in co-lon carcinoma cells and avoids transfection of undesired DNA,” vol. 3(5): 793-800 (2001). [cited by applicant]
Schoonjans, R. et al., “Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives,” Journ of Immunology, vol. 165(12): 7050-7057 (2000). [cited by applicant]
Shields, R. L. et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcgR*,” The Journal of Biological Chemistry… [cited by applicant]
Snajdauf, M. et al., “The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials,” Frontiers Media S.A, vol. 8: 628332 (2021). [cited by applicant]
Strating, E. et al., “Co-cultures of colon cancer cells and cancer-associated fibroblasts recapitulate the aggressive features of mesenchymal-like colon cancer,” Frontiers Research Foundation, vol. 14: 1-16 (2023). [cited by applicant]